Across TCGA pan-cancer cohorts, TMEM51 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM51 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in thymoma (THYM), where higher TMEM51 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM51 expression acts as an unfavorable survival marker.
THYM, LUSC, and LUAD are the cancer types where TMEM51 Mutation most reproducibly stratifies survival.